Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)

Subscribe to Selected New Research on Peptidyl-Dipeptidase A

8818 relevant articles (499 outcomes, 1523 trials/studies) found for this Bio-Agent

Description: A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, -Xaa-*-Xbb-Xcc, when neither Xaa nor Xbb is Pro. It is a Cl(-)-dependent, zinc glycoprotein that is generally membrane-bound and active at neutral pH. It may also have endopeptidase activity on some substrates. (From Enzyme Nomenclature, 1992) EC 3.4.15.1.

Also Known As:

Angiotensin Converting Enzyme; Angiotensin I-Converting Enzyme; Carboxycathepsin; Dipeptidyl Peptidase A; Kininase A; Angiotensin I Converting Enzyme; Peptidyl Dipeptidase A; Antigens, CD143; CD143 Antigens; Kininase II

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Fukui, Hiroshi: 6 articles (06/2007 - 12/2003)
2.	Kitade, Mitsuteru: 6 articles (06/2007 - 12/2003)
3.	Noguchi, Ryuichi: 6 articles (06/2007 - 12/2003)
4.	Ikenaka, Yasuhide: 6 articles (06/2007 - 12/2003)
5.	Yoshiji, Hitoshi: 6 articles (06/2007 - 12/2003)
6.	Yamazaki, Masaharu: 6 articles (06/2007 - 12/2003)
7.	Goracy, Iwona: 6 articles (03/2007 - 01/2005)
8.	Adam, Albert: 5 articles (01/2008 - 10/2002)
9.	Huskić, Jasminko: 5 articles (05/2007 - 01/2004)
10.	Pfeffer, Marc A: 5 articles (07/2006 - 11/2004)

Related Diseases

1.	Heart Failure 12/01/2002 - "This is important since interventions that have been shown to improve mortality in patients with heart failure such as angiotensin converting enzyme inhibitor and beta-blockers had a favorable impact on the LV remodeling process. " 03/28/2008 - "OBJECTIVE: Angiotensin-converting enzyme inhibitor (ACEI) is beneficial in patients with congestive heart failure (CHF). " 01/01/2002 - "The overall high rates of adherence to angiotensin-converting enzyme inhibitor therapy observed among heart failure clinic patients is consistent with research that shows improved outcomes for patients managed in heart failure clinics. " 08/01/2000 - "Although inhibitors of angiotensin-converting enzyme (ACE) have improved the treatment of chronic heart failure (CHF), mortality related to this disorder remains unacceptably high. " 08/01/1996 - "A randomized, 48-week, double-blind study was performed to investigate the safety and efficacy of 'high' in comparison to continued 'low' angiotensin converting enzyme inhibitor therapy in severe heart failure. " Order ALL the reference details at left...
2.	Hypertension (High Blood Pressure) 01/01/2001 - "The role of the renin-angiotensin-aldosterone system in the pathogenesis of hypertensive disease has long been recognized, and the interruption of this cascade with angiotensin-converting enzyme-I has been beneficial in the management of hypertension. " 12/19/1985 - "Long-term studies are needed to find out whether this angiotensin-converting enzyme inhibitor is superior to a diuretic as initial treatment of arterial hypertension." 11/01/1989 - "These findings suggested that urinary excretion of GAA may be a more sensitive marker than AER, BMG or NAG in hypertension and angiotensin-converting enzyme inhibitor and Ca entry blocker can be useful in the treatment of patients with essential hypertension with renal damage." 12/01/1995 - "1. We investigated the protective effects of an angiotensin-converting enzyme inhibitor (ACEI) and a Ca antagonist on vascular injury in hypertension. " 01/01/2005 - "[Level of endothelial vasodilatation and activity of angiotensin converting enzyme as criterion of efficacy of therapy in patients with mild and moderate hypertension]" Order ALL the reference details at left...
3.	Myocardial Infarction 09/26/1994 - "This article reviews the recent trials using angiotensin-converting enzyme inhibition after myocardial infarction and will explore the reasons why angiotensin-converting enzyme inhibition seems to be beneficial in this clinical setting." 06/15/1999 - "BACKGROUND: Angiotensin converting enzyme (ACE) inhibition after myocardial infarction is associated with an improvement in plasma fibrinolytic parameters. " 07/01/1996 - "Angiotensin-converting enzyme inhibition started in the subacute or late phase after myocardial infarction has been shown to improve prognosis. " 04/01/1994 - "Efficacy of angiotensin-converting enzyme inhibition and AT1 receptor blockade on cardiac pump performance after myocardial infarction in rats." 02/01/2009 - "CONCLUSIONS: This study confirms the benefits of a high dose of angiotensin-converting enzyme inhibitor for the secondary prevention of cardiovascular risk among patients with a history of myocardial infarction and/or revascularization." Order ALL the reference details at left...
4.	Proteinuria 11/01/2009 - "Proteinuria resolved completely following the initiation of a gluten-free diet, without the use of immunosuppressive therapy and despite tapering of angiotensin-converting enzyme inhibitor. " 04/27/1992 - "We have previously reported that angiotensin-converting enzyme (ACE) inhibition in Munich Wistar Fromter/Ztm (MWF/Ztm) rats resulted in a significant reduction of proteinuria, in respect to untreated animals, and that treated animals were protected against the development of glomerular sclerotic lesions. " 07/01/2003 - "Remission of nephrotic range proteinuria has also been reported in some patients with type 1 diabetes from the Collaborative Study Group during a median follow-up of 3 years of angiotensin-converting enzyme (ACE) inhibitor administration; no deterioration of renal function was observed in these patients. " 04/01/2005 - "[Influence of angiotensin-converting enzyme gene polymorphism on the anti-proteinuria efficacy of angiotensin-converting enzyme inhibitor in Han nationality of southern Sichuan province in China]" 07/01/2007 - "The maximum mean percent reduction was attained at 3 months (47% +/- 27%), was not influenced by the levels of baseline proteinuria, and was similar in patients receiving or not receiving angiotensin-converting enzyme inhibition at the start of the study. " Order ALL the reference details at left...
5.	Diabetic Nephropathies (Diabetic Nephropathy) 03/01/1995 - "In patients with diabetic nephropathy, angiotensin converting enzyme (ACE) inhibition has been shown to be more effective in this regard than conventional antihypertensive therapy. " 09/07/1996 - "OBJECTIVE: To evaluate the concept that an insertion/deletion polymorphism of the angiotensin converting enzyme gene predicts the therapeutic efficacy of inhibition of angiotensin converting enzyme on progression of diabetic nephropathy. " 04/01/1992 - "Angiotensin converting enzyme (ACE) inhibition has shown promising results in diabetic nephropathy, but long-term results on survival are not available. " 11/01/2009 - "Identification of specific angiotensin-converting enzyme variants and haplotypes that confer risk and protection against type 2 diabetic nephropathy." 07/01/2001 - "It should be recalled that development of treatment modalities occurred in reverse order: in the early 1980s, antihypertensive treatment of diabetic nephropathy was introduced, and in the early 1990s, primary and secondary prevention with improved glycaemic control and angiotensin-converting enzyme inhibition. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
2.	Captopril (Capoten)
3.	Enalapril
4.	Angiotensin II
5.	Angiotensins
6.	Angiotensin Receptors (Angiotensin II Receptor)
7.	Perindopril
8.	Calcium
9.	Ramipril (Altace)
10.	Lisinopril (Prinivil)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Surgical Instruments (Clip)
3.	Renal Dialysis (Hemodialysis)
4.	Oral Administration
5.	Drug Therapy (Chemotherapy)

Best Treatments:
Research Summary Report
on Heart Failure

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2785 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>